Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.US-based natural products maker, ChromaDex has launched a new patented nicotinamide riboside (NR) product, Niagen, which is considered as the next generation Niacin (Vitamin B3).
Subscribe to our email newsletter
Niagen joins the portfolio of B-vitamin ingredients that are used in multi-vitamins, nutraceuticals, weight-loss, energy drinks, sports nutrition, meal replacements, and infant formula, food and beverage products.
ChromaDex founder and CEO Frank Jaksch said that by solving the challenge of producing NR on a commercially viable scale, the company has achieved the first step in unlocking the potential of this new vitamin.
"The formal launch of NIAGEN, our branded nicotinamide riboside, will immediately allow dietary supplement, and food & beverage companies to include NIAGEN in product formulations," Jaksch added.
"We are in the final stages of completing the design of our first human clinical study for NIAGEN."
Dubbed as Miracle Molecule, NR is a newly discovered vitamin and a more potent version of Niacin.
NR helps in the improvement of fatty acid oxidation, mitochondrial activity, and resistance to negative consequences of high-fat diets, protection against oxidative stress, prevention of peripheral neuropathy and blocking muscle degeneration.
In the past two years, ChromaDex has secured a patent portfolio for NR by separately acquiring rights from Cornell University, Dartmouth College and Washington University.